Contralateral risk-reducing mastectomy in BRCA1 and BRCA2 mutation carriers and other high-risk women in the Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer (kConFab)

BE Kiely; MA Jenkins; JM McKinley; ML Friedlander; RL Milne; SA McLachlan; JL Hopper; KA Phillips

Journal article

Contralateral risk-reducing mastectomy in BRCA1 and BRCA2 mutation carriers and other high-risk women in the Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer (kConFab)

BE Kiely, MA Jenkins, JM McKinley, ML Friedlander, RL Milne, SA McLachlan, JL Hopper, KA Phillips

Breast Cancer Research and Treatment | Published : 2010

DOI: 10.1007/s10549-009-0497-8

Abstract

The purpose of this study is to determine the prevalence and predictors of contralateral risk-reducing mastectomy (CRRM) in Australasian women at high familial risk of a second primary breast cancer (BC). Participants were women with unilateral BC and a strong family history of the disease, including BRCA1/2 mutation carriers. Data were collected through interview, selfadministered questionnaire and review of pathology and surgical reports. Associations between CRRM and potential predictors were assessed using multivariate logistic regression. Of 1,018 women (median follow-up 11.1 years), 154 (15%) underwent CRRM, 43% of these within 12 months of initial BC surgery. More likely to undergo CR..

View full abstract

University of Melbourne Researchers

Mark Jenkins Author

Roger Milne Author

Sue-Anne McLachlan Author

Kelly Phillips Author

Related Projects (2)

RISK FACTORS, SCREENING, PROPHYLAXIS AND OUTCOMES IN INDIVIDUALS FROM BREAST CANCER FAMILIES: KCONFAB FOLLOW-UP STUDY

Having a strong family history of breast cancer is one of the most important risk factors for the disease. Two major genes, BRCA1 and BRCA2,..

How can the risk of breast cancer be reduced in those with a strong family history of the disease?

Having a strong family history for breast cancer is one of the most important risk factors for the disease. Two major genes, BRCA1 and BRCA2..

Grants

Awarded by National Health and Medical Research Council

Funding Acknowledgements

This study was funded by the National Health and Medical Research Council (NHMRC) of Australia (# 145684, 288704, 454508). KA Phillips is the Cancer Council Victoria Dr John Colebatch Clinical Research Fellow. JL Hopper is an Australia Fellow of the NHMRC and Victorian Breast Cancer Research Consortium Group Leader. kConFab is supported by grants from the National Breast Cancer Foundation, the National Health and Medical Research Council of Australia, the Queensland Cancer Fund, the Cancer Councils of New South Wales, Victoria, Tasmania and South Australia, the Cancer Foundation of Western Australia, Perpetual Philanthropic Foundations of New South Wales and the Breast Cancer Research Association.